OtherChemotherapy, Antibiotics, and Gene Therapy
Disruption of ovarian cancer STAT3 and p38 signaling with a small molecule inhibitor of PTP4A3 phosphatase
John S. Lazo, Kelly N. Isbell, Sai Ashish Vasa, Danielle C. Llaneza, Ettore J. Rastelli, Peter Wipf and Elizabeth R. Sharlow
Journal of Pharmacology and Experimental Therapeutics February 21, 2023, JPET-AR-2022-001401; DOI: https://doi.org/10.1124/jpet.122.001401
John S. Lazo
1Pharmacology, University of Virginia, United States
Kelly N. Isbell
2Biology, KeViRx, Inc., United States
Sai Ashish Vasa
2Biology, KeViRx, Inc., United States
Danielle C. Llaneza
1Pharmacology, University of Virginia, United States
Ettore J. Rastelli
3Chemistry, University of Pittsburgh, United States
Peter Wipf
4Pittsburgh, United States
Elizabeth R. Sharlow
1Pharmacology, University of Virginia, United States

Jump to comment:
No eLetters have been published for this article.
In this issue
OtherChemotherapy, Antibiotics, and Gene Therapy
PTP4A3 and ovarian cancer
John S. Lazo, Kelly N. Isbell, Sai Ashish Vasa, Danielle C. Llaneza, Ettore J. Rastelli, Peter Wipf and Elizabeth R. Sharlow
Journal of Pharmacology and Experimental Therapeutics February 21, 2023, JPET-AR-2022-001401; DOI: https://doi.org/10.1124/jpet.122.001401
OtherChemotherapy, Antibiotics, and Gene Therapy
PTP4A3 and ovarian cancer
John S. Lazo, Kelly N. Isbell, Sai Ashish Vasa, Danielle C. Llaneza, Ettore J. Rastelli, Peter Wipf and Elizabeth R. Sharlow
Journal of Pharmacology and Experimental Therapeutics February 21, 2023, JPET-AR-2022-001401; DOI: https://doi.org/10.1124/jpet.122.001401
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement